Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10191988 | 0.86 | HPGD (0.71) | HSD17B10HPGDMAPK1ALDH1A1FAAH | |
| SCHEMBL8211088 | 0.85 | MAPK1 (0.57) | HSD17B10HPGDMAPK1ALDH1A1FAAH | |
| SCHEMBL10192104 | 0.85 | HSD17B10 (0.54) | HSD17B10HPGDMAPK1ALDH1A1FAAH | |
| SCHEMBL3424143 | 0.84 | MAPK1 (0.69) | HSD17B10HPGDMAPK1ALDH1A1FAAH | |
| SCHEMBL14451908 | 0.84 | HSD17B10 (0.71) | HSD17B10HPGDMAPK1ALDH1A1FAAH | |
| SCHEMBL10192011 | 0.84 | RAB9A (0.72) | HSD17B10HPGDMAPK1ALDH1A1FAAH | |
| SCHEMBL10192012 | 0.82 | HPGD (0.56) | HSD17B10HPGDMAPK1ALDH1A1FAAH | |
| SCHEMBL10192053 | 0.81 | HSD17B10 (0.57) | HSD17B10HPGDMAPK1ALDH1A1FAAH | |
| SCHEMBL10192044 | 0.81 | MEN1 (0.69) | HSD17B10HPGDMAPK1ALDH1A1FAAH | |
| SCHEMBL7980860 | 0.81 | NPC1 (0.62) | HPGDMAPK1ALDH1A1FAAHCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | EIF2AK2, INMT, IDO1 | HSD17B10 2200/4885HPGD 3067/4885MAPK1 3303/4885 |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | HSD17B10 535/4885HPGD 1342/4885MAPK1 4616/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | HSD17B10 886/4885HPGD 1033/4885MAPK1 4384/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | HSD17B10 1276/4885HPGD 3255/4885MAPK1 4248/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | HSD17B10 1276/4885HPGD 3255/4885MAPK1 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.